Literature DB >> 3753694

Evolution of the visual prognosis of prematures in the last 20 years.

J P Gerhard, D Willard, J Messer.   

Abstract

Ophthalmoscopic examinations were performed on 5678 prematures, born between 1964 and 1984, by the same investigator in the same neonatal care unit. Three periods can be differentiated. In the first period (1964-1970) retinal disorders were frequent (20%), a quarter of them severe (stages 3-5). The inspiratory fraction of oxygen was the only oxymetric factor that was monitored. In the second period (1970-1977), less severe forms were observed, but still 4.5% of stage 1 and 8.7% of stage 2 (mild forms) were assessed. During this period, oxygen partial pressure was measured every 6 h in arterial blood whenever the inspiratory fraction of oxygen exceeded 0.3. In the last period (1977-1984), no severe forms were observed and mild forms amounted to only 0.9%. In this period, oxygen partial pressure was continuously monitored transcutaneously, whenever the inspiratory fraction of oxygen exceeded 0.21. Such data show that there is an association between better oxygen monitoring and the dramatically reduced incidence of retinopathy in prematures (RP).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753694     DOI: 10.1007/bf02144137

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  4 in total

1.  Vision loss due to retinopathy of prematurity.

Authors:  D L Phelps
Journal:  Lancet       Date:  1981-03-14       Impact factor: 79.321

2.  [Visual future of prematures].

Authors:  J P Gerhard; D Willard; J F Risse; J J Kuss; J Messer
Journal:  Ophthalmologica       Date:  1978       Impact factor: 3.250

Review 3.  A reexamination of the role of oxygen in retrolental fibroplasia.

Authors:  J F Lucey; B Dangman
Journal:  Pediatrics       Date:  1984-01       Impact factor: 7.124

4.  Retrolental fibroplasia: a study of the incidence and aetiological factors, 1977-1979.

Authors:  C G Keith; S T Smith; B J Lansdell
Journal:  Med J Aust       Date:  1981-11-28       Impact factor: 7.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.